Nabriva Therapeutics Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

H. Hogan

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	1.3yrs
CEO ownership	n/a
Management average tenure	1.4yrs
Board average tenure	6.8yrs

Recent management updates

Recent updates

Nabriva Therapeutics to effect 1-for-25 reverse stock split

Sep 15

Nabriva stock soars 19% on distribution deal with Er-Kim for bacterial pneumonia drug Xenleta

Jul 18

Need To Know: The Consensus Just Cut Its Nabriva Therapeutics plc (NASDAQ:NBRV) Estimates For 2022

Apr 04

Bullish: Analysts Just Made A Noticeable Upgrade To Their Nabriva Therapeutics plc (NASDAQ:NBRV) Forecasts

Aug 11

We Think Some Shareholders May Hesitate To Increase Nabriva Therapeutics plc's (NASDAQ:NBRV) CEO Compensation

Jul 22

CEO

H. Hogan (61 yo)

1.3yrs

Tenure

Mr. H. Michael Hogan III is Chief Executive Officer of Nabriva Therapeutics plc from July 6, 2023. He serves as Director of Metacrine, Inc. since March 23, 2023. He is Director of Otonomy, Inc. from Februa...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Colin Broom	Director	7.2yrs	US$40.00k	no data
H. Hogan	Chief Executive Officer	1.3yrs	no data	no data
David Maggio	Chief Financial Officer	1.4yrs	no data	no data

1.4yrs

Average Tenure

64yo

Average Age

Experienced Management: NBRV.F's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Colin Broom	Director	7.4yrs	US$40.00k	no data
Daniel Burgess	Independent Chairman of the Board	7.4yrs	US$90.00k	no data
Mark H. Corrigan	Independent Director	3.4yrs	US$50.00k	no data
Stephen Webster	Independent Director	7.4yrs	US$65.00k	no data
Steven Gelone	Director	3.7yrs	US$579.23k	no data
Charles Rowland	Independent Director	7.4yrs	US$55.00k	no data
Theodore Schroeder	Director	6.3yrs	US$753.56k	no data
Lisa Dalton	Independent Director	3.4yrs	US$47.50k	no data

6.8yrs

Average Tenure

64.5yo

Average Age

Experienced Board: NBRV.F's board of directors are considered experienced (6.8 years average tenure).

Nabriva Therapeutics Management

Management criteria checks 1/4

Key information

Recent management updates

Nabriva Therapeutics plc Appoints Dave Maggio as Chief Financial Officer

Nabriva Therapeutics plc Appoints Christopher Naftzger as Interim Chief Executive Officer

Nabriva Therapeutics plc, Annual General Meeting, Aug 11, 2022

CEO & Director recently bought US$57k worth of stock

CEO & Director recently bought US$57k worth of stock

Less than half of directors are independent

Recent updates

Nabriva Therapeutics plc Files Form 15

Nasdaq to Delist the Ordinary Shares of Nabriva Therapeutics

Nabriva Therapeutics plc(OTCPK:NBRV.F) dropped from NASDAQ Composite Index

Nabriva Therapeutics Receives A Delisting Determination Letter from Nasdaq

Nabriva Therapeutics plc Appoints Dave Maggio as Chief Financial Officer

Nabriva Therapeutics plc announced delayed 10-Q filing

Nabriva Therapeutics plc Appoints Christopher Naftzger as Interim Chief Executive Officer

Nabriva Therapeutics plc Announces Positive Topline Results from Phase 1 Trial of XENLETA (lefamulin) in Adult Patients with Cystic Fibrosis

Nabriva Therapeutics plc to Report Q3, 2022 Results on Nov 10, 2022

Nabriva Therapeutics to effect 1-for-25 reverse stock split

Nabriva Therapeutics plc Completes Patient Enrollment in Phase 1 Trial of XENLETA(R) (lefamulin) in Adult Patients with Cystic Fibrosis

Nabriva Therapeutics plc to Report Q2, 2022 Results on Aug 03, 2022

Nabriva stock soars 19% on distribution deal with Er-Kim for bacterial pneumonia drug Xenleta

Nabriva Therapeutics plc, Annual General Meeting, Aug 11, 2022

The Nasdaq Stock Market LLC Approves Nabriva Therapeutics' Transfer from the Nasdaq Global Select Market to the Nasdaq Capital Market

Consensus revenue estimates fall by 10%

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Nabriva Therapeutics plc to Report Q1, 2022 Results on May 05, 2022

No longer forecast to breakeven

Nabriva Therapeutics plc Announces First Patient Enrolled in Phase 1 Trial of Xenleta® (Lefamulin) in Adult Patients with Cystic Fibrosis

Consensus revenue estimates fall by 17%

Need To Know: The Consensus Just Cut Its Nabriva Therapeutics plc (NASDAQ:NBRV) Estimates For 2022

No longer forecast to breakeven

Forecast to breakeven in 2024

CEO & Director recently bought US$57k worth of stock

Third quarter 2021 earnings released: US$0.21 loss per share (vs US$0.90 loss in 3Q 2020)

CEO & Director recently bought US$57k worth of stock

Consensus revenue estimates increase to US$29.6m

Bullish: Analysts Just Made A Noticeable Upgrade To Their Nabriva Therapeutics plc (NASDAQ:NBRV) Forecasts

Second quarter 2021 earnings released: US$0.29 loss per share (vs US$1.37 loss in 2Q 2020)

Independent Director George Talbot has left the company

Less than half of directors are independent

We Think Some Shareholders May Hesitate To Increase Nabriva Therapeutics plc's (NASDAQ:NBRV) CEO Compensation

No longer forecast to breakeven

Consensus forecasts updated

Sinovant Sciences and Nabriva Therapeutics plc Announce Positive Topline Results from Phase 3 Trial of Lefamulin in Chinese Adults with Community Acquired Bacterial Pneumonia (CABP)

Consensus forecasts updated

First quarter 2021 earnings released: US$0.53 loss per share (vs US$2.46 loss in 1Q 2020)

Nabriva Therapeutics plc 2021 Q1 - Results - Earnings Call Presentation

Nabriva Therapeutics plc has completed a Follow-on Equity Offering in the amount of $33.7 million.

Consensus revenue estimates increase to US$30.8m

Consensus forecasts updated

Nabriva Publishes Clinical Data Analysis Highlighting Benefits of Outpatient Management of Community Acquired Bacterial Pneumonia (CABP) with Oral XENLETA® (lefamulin)

Chief Financial Officer has left the company

Nabriva Therapeutics Appoints Steven Gelone to Its Board of Directors

Full year 2020 earnings released: US$5.41 loss per share (vs US$11.15 loss in FY 2019)

Revenue and earnings beat expectations

Nabriva Therapeutics plc to Report Q4, 2020 Results on Mar 11, 2021

New 90-day low: US$1.92

Nabriva Therapeutics plc Announces A Hearing on May 14, 2021

Nabriva Therapeutics plc Announces the Publication of A Study Documenting the High Rates of Macrolide-Resistant Streptococcus Pneumoniae Throughout the United States

When Will Nabriva Therapeutics plc (NASDAQ:NBRV) Breakeven?

Nabriva Therapeutics Announces Retirement of Gary Sender as Chief Financial Officer, Effective as of March 12, 2021

Nabriva Therapeutics announces proposed public offering

New 90-day low: US$3.40

Nabriva Therapeutics and Sinovant Sciences Restructure License Agreement for XENLETA for Community-Acquired Bacterial Pneumonia in China

Nabriva Therapeutics shares gain as Sinovant expands Xenleta support in China

Nabriva Therapeutics plc 2020 Q3 - Results - Earnings Call Presentation

Third quarter 2020 earnings released: US$0.09 loss per share

Revenue and earnings beat expectations

Nabriva Therapeutics plc to Report Q3, 2020 Results on Nov 05, 2020

Analysts update estimates

New 90-day low: US$0.51

Nabriva Therapeutics plc Announces XENLETA Demonstrates High Efficacy in Patients of Advanced Age with Community-Acquired Bacterial Pneumonia (CABP)

New 90-day low: US$0.53

New 90-day low - US$0.59

Earnings released

Nabriva Therapeutics plc to Report Q2, 2020 Results on Aug 06, 2020

CEO